Technical Articles

In the field of immune checkpoint research, the clinical value of CTLA-4 and PD-1 has been confirmed, but the limited efficacy has driven the exploration of new generation co inhibitory receptors such as Lag-3 and TIMD3. TIMD3 (T-cell immunoglobulin -3, also known as CD366) has become one of the core targets in immune regulation research due to its unique expression pattern and functional mechanism.